Covalon Technologies Ltd.
TSX VENTURE : COV

Covalon Technologies Ltd.

September 08, 2005 13:54 ET

Jacques Lemmetti Appointed Chairman of the Board at Covalon

MISSISSAUGA, ONTARIO--(CCNMatthews - Sept. 8, 2005) - Mr. Gary E. German, Chairman of Covalon Technologies Ltd. (Covalon) (TSX VENTURE:COV) is very pleased to announce that effective September 15, 2005, he will be succeeded as Chairman of the Board by Mr. Jacques M. Lemmetti.

Covalon Technologies has very successfully transitioned from a non-public entity developing proprietary products to now aggressively opening markets with multiple products and strategic industry franchise relationships. Mr. Lemmetti's vast experience in medical products and particularly in the advanced wound care field will help guide the company's future direction. Prior to accepting this new responsibility, Mr. Lemmetti served as president and CEO of Hartmann-Conco, Inc. in the USA. There he transformed a commodity oriented company into an emerging player in the wound care arena. Previously, Mr. Lemmetti, acting as President, was the driving force behind the emergence of Smith & Nephew as one of the leading wound care companies in the USA. A Canadian expatriate, he has many years of experience in the Canadian market as well as significant exposure to the European market where he lived and directed a major medical products company. Mr. Lemmetti will contribute significantly to the Covalon team's strategy and effectiveness. The Board looks forward to receiving more of Jacques' time and industry knowledge both in the America's and Europe.

Mr. German will continue as a Director and Chair the Governance and Compensation committees.

Covalon Technologies Ltd. is a company with advanced medical products that has developed and patented advanced therapeutic biomaterials for wound care and surgical applications and coatings. Polymer chemistry and surface coating technology have been combined to create a range of time-release drug delivery platforms that are applied to many medical devices to treat many critical conditions. A variety of applications for these technologies have been identified and specific products have been developed. The products offer features and benefits providing solutions to many of the problems caused by current devices and their material properties which are used by most medical device manufacturers and suppliers. The problems include infection, poor biocompatibility, and microbial attachment.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this release.


Contact Information

  • Covalon Technologies Ltd.
    William Jackson
    CFO & COO
    (905) 568-8400
    (905) 568-5200 (FAX)
    www.covalon.com